(2023)
PARIS undergoes liquid–liquid phase separation and poly(ADP-ribose)-mediated solidification.
EMBO REPORTS.
24,
11
(2023)
Identification and evaluation of midbrain specific longevity-related genes in exceptionally long-lived but healthy mice.
FRONTIERS IN AGING NEUROSCIENCE.
14,
-
(2022)
Pharmacological inhibition of AIMP2 aggregation attenuates ?-synuclein aggregation and toxicity in Parkinson?s disease.
BIOMEDICINE & PHARMACOTHERAPY.
156,
-
(2022)
Synthetic Peucedanocoumarin IV Prevents alpha-Synuclein Neurotoxicity in an Animal Model of Parkinson's Disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
23,
15
(2021)
PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease.
SCIENCE TRANSLATIONAL MEDICINE.
13,
604
(2021)
Effects of 1 alpha,25-Dihydroxyvitamin D-3 on the Pharmacokinetics of Procainamide and Its Metabolite N-Acetylprocainamide, Organic Cation Transporter Substrates, in Rats with PBPK Modeling Approach.
PHARMACEUTICS.
13,
8
(2021)
Sensitive electrochemical biosensor combined with isothermal amplification for point-of-care COVID-19 tests.
BIOSENSORS & BIOELECTRONICS.
182,
(2020)
Activation of the Akt1-CREB pathway promotes RNF146 expression to inhibit PARP1-mediated neuronal death.
SCIENCE SIGNALING.
13,
663
(2020)
Differential Effects of 1 alpha,25-Dihydroxyvitamin D-3 on the Expressions and Functions of Hepatic CYP and UGT Enzymes and Its Pharmacokinetic Consequences In Vivo.
PHARMACEUTICS.
12,
11
(2020)
Brain Endothelial P-Glycoprotein Level Is Reduced in Parkinson's Disease via a Vitamin D Receptor-Dependent Pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
21,
22
(2020)
Amyloid-like oligomerization of AIMP2 contributes to alpha-synuclein interaction and Lewy-like inclusion.
SCIENCE TRANSLATIONAL MEDICINE.
12,
569
(2020)
Novel Nasal Epithelial Cell Markers of Parkinson's Disease Identified Using Cells Treated with alpha-Synuclein Preformed Fibrils.
JOURNAL OF CLINICAL MEDICINE.
9,
7
(2020)
Deubiquitinase USP29 Governs MYBBP1A in the Brains of Parkinson's Disease Patients.
JOURNAL OF CLINICAL MEDICINE.
9,
1
(2019)
The regulation of glutamic acid decarboxylases in GABA neurotransmission in the brain.
ARCHIVES OF PHARMACAL RESEARCH.
42,
12
(2019)
Therapeutic Evaluation of Synthetic Peucedanocoumarin III in an Animal Model of Parkinson's Disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
20,
21
(2019)
Scalable and Isotropic Expansion of Tissues with Simply Tunable Expansion Ratio.
ADVANCED SCIENCE.
6,
22
(2019)
Quantitative analysis of nasal transcripts reveals potential biomarkers for Parkinson's disease.
SCIENTIFIC REPORTS.
9,
999
(2019)
Cell-Based Screen Using Amyloid Mimic beta 23 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of alpha-Synuclein and Huntingtin Aggregates.
MOLECULES AND CELLS.
42,
6
(2019)
Rhododendrin-Induced RNF146 Expression via Estrogen Receptor Activation is Cytoprotective Against 6-OHDA-Induced Oxidative Stress.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
20,
7
Patent/Intellectual Property
파킨슨 질환 동물 모델 및 이를 이용한 스크리닝 방법.
10-2018-0135355.
20201229.
KOREA, REPUBLIC OF
ZNF146의 인산화-타이로신 잔기 특이적 항체 및 이의 용도.
10-2017-0169065.
20200302.
KOREA, REPUBLIC OF
도파민 신경세포 특이적 발현 제어 시스템.
10-2018-0097376.
20200121.
KOREA, REPUBLIC OF
콧물액을 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트.
10-2018-0035157.
20200116.
KOREA, REPUBLIC OF
노화 모델 제조 방법 및 이에 의해 제조된 세포 또는 동물 노화 모델.
10-2017-0139195.
20190819.
KOREA, REPUBLIC OF
퇴행성 뇌질환의 치료 또는 예방용으로서의 RNF146 발현 유도 약학 조성물.
10-2017-0036003.
20181004.
KOREA, REPUBLIC OF
퓨세다노쿠마린 III를 포함하는 퇴행성 뇌질환의 치료 또는 예방용 약학 조성물.
10-2017-0051223.
20181004.
KOREA, REPUBLIC OF
퇴행성 뇌질환 치료제 스크리닝 방법 및 이를 위한 키트.
10-2017-0024563.
20180808.
KOREA, REPUBLIC OF
